AXL and non-small cell lung carcinoma: Of the 11 EGFR-mutated NSCLC tumors for osimertinib, high, intermediate, low, and no AXL expression was observed in three (27.2%), one (18.2%), seven (63.6%), and zero (0.0%) specimens, respectively.